Stock Scorecard



Stock Summary for Vanda Pharmaceuticals Inc (VNDA) - $4.90 as of 11/20/2024 8:51:27 PM EST

Total Score

12 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for VNDA

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for VNDA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for VNDA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for VNDA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for VNDA (32 out of 90)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 5
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0

Latest News for for VNDA

New Strong Buy Stocks for November 14th 11/14/2024 10:59:00 AM
Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst - Vanda Pharma ( NASDAQ:VNDA ) 11/1/2024 6:05:00 PM
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More 10/17/2024 4:04:00 PM
VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises 10/15/2024 3:51:00 PM
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More 9/26/2024 4:06:00 PM
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis - Illumina ( NASDAQ:ILMN ) , Fulcrum Therapeutics ( NASDAQ:FULC ) 9/20/2024 7:23:00 PM
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis 9/20/2024 3:37:00 PM
Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today 9/19/2024 9:20:00 PM
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments 9/19/2024 6:20:00 PM
Why Is Vanda Pharmaceuticals Stock Falling On Thursday? - Vanda Pharma ( NASDAQ:VNDA ) 9/19/2024 2:33:00 PM

Financial Details for VNDA

Company Overview

Ticker VNDA
Company Name Vanda Pharmaceuticals Inc
Country USA
Description Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company is headquartered in Washington, the District of Columbia.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date 2/5/2025

Stock Price History

Last Day Price 4.90
Price 4 Years Ago 13.14
Last Day Price Updated 11/20/2024 8:51:27 PM EST
Last Day Volume 396,102
Average Daily Volume 736,834
52-Week High 6.75
52-Week Low 3.44
Last Price to 52 Week Low 42.44%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE 36.07
Free Cash Flow Ratio 2.85
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 4.85
Total Cash Per Share 1.72
Book Value Per Share Most Recent Quarter 9.28
Price to Book Ratio 0.54
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 1.53
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 58,308,000
Market Capitalization 285,709,200
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 5.72%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -95.90%
Annual Earnings Growth -60.02%
Reported EPS 12 Trailing Months -0.19
Reported EPS Past Year -0.24
Reported EPS Prior Year 0.05
Net Income Twelve Trailing Months -16,388,000
Net Income Past Year 2,509,000
Net Income Prior Year 6,275,000
Quarterly Revenue Growth YOY 22.80%
5-Year Revenue Growth -0.05%
Operating Margin Twelve Trailing Months -0.23

Balance Sheet

Total Cash Most Recent Quarter 100,497,000
Total Cash Past Year 135,821,000
Total Cash Prior Year 135,029,000
Net Cash Position Most Recent Quarter 100,497,000
Net Cash Position Past Year 135,821,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 544,910,000
Total Stockholder Equity Prior Year 527,198,000
Total Stockholder Equity Most Recent Quarter 541,223,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -18,201,000
Free Cash Flow Per Share Twelve Trailing Months -0.31
Free Cash Flow Past Year 12,418,000
Free Cash Flow Prior Year 31,305,000

Options

Put/Call Ratio 0.48
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.15
MACD Signal 0.06
20-Day Bollinger Lower Band 4.17
20-Day Bollinger Middle Band 5.14
20-Day Bollinger Upper Band 6.12
Beta 0.77
RSI 69.52
50-Day SMA 4.79
150-Day SMA 7.32
200-Day SMA 9.84

System

Modified 11/19/2024 3:45:19 PM EST